Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Induced Mesenchymal Stem Cell
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Novecite
Deal Size : $56.0 million
Deal Type : Licensing Agreement
Details : NoveCite will develop and commercialize Novellus's iMSCs to treat acute respiratory conditions with a near term focus on Acute Respiratory Distress Syndrome ("ARDS") associated with COVID-19.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : $5.0 million
October 13, 2020
Lead Product(s) : Induced Mesenchymal Stem Cell
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Novecite
Deal Size : $56.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Plixorafenib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Pontifax Medison Debt Financing
Deal Size : $57.0 million
Deal Type : Series C Financing
Novellus Closes $57M Series C Financing
Details : Proceeds will fund the clinical development of PLX-8394 for patients with BRAF fusions and glioma patients with BRAF mutations.
Product Name : PLX-8394
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 21, 2020
Lead Product(s) : Plixorafenib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Pontifax Medison Debt Financing
Deal Size : $57.0 million
Deal Type : Series C Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Citius Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Novellus, a Cambridge, Mass-based cell engineering company, has developed patented, non-immunogenic mRNA-based induced mesenchymal stem cell (iMSC) platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 10, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Citius Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Mesenchymal Stem Cell
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Undisclosed
Sponsor : Citius Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for ARDS in COVID-19
Details : Citius signed an exclusive six-month option agreement to in-license a stem-cell therapy for acute respiratory distress syndrome from a subsidiary of Novellus.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 04, 2020
Lead Product(s) : Mesenchymal Stem Cell
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Undisclosed
Sponsor : Citius Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement